NCT07006025View on ClinicalTrials.gov

A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)

PHASE1RecruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

June 3, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

March 30, 2027

Conditions

MDS

Interventions

DRUG

Decitabine

Oral tetrahydrouridine and oral decitabine capsule

Trial Locations (1)

10467

RECRUITING

Montefiore Einstein Medical Center, The Bronx

Sponsors

Lead Sponsor

EpiDestiny, Inc.

All Listed Sponsors

lead

EpiDestiny, Inc.

INDUSTRY

NCT07006025 - A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS) | Biotech Hunter | Biotech Hunter